Phase 3 NEURO-TTRansform Results Indicate Eplontersen as a Promising Agent for hATTR Polyneuropathy.

Published Date: 04 May 2023

Patients receiving eplontersen showed sustained TTR concentration reduction, halted neuropathy impairment progression, and improved quality of life after 66 weeks of treatment.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Stem Cell Selection Unneeded for SSc Transplant Therapy?

2.

Lung Transplant for Lung Cancer: Promising, in Rare Cases

3.

Rural-urban disparities seen in cervical cancer

4.

Obesity linked to subsequent neoplasms in childhood cancer survivors

5.

New policy review highlights the importance of health-related quality of life in advanced cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot